Laparoscopic Hysterectomy

Published on May 13, 2014 by admin

Text-Size:A A A+

Women who were diagnosed with cancer that spread to other parts of the body after a power morcellator-aided laparoscopic hysterectomy may be eligible to file a lawsuit. This type of procedure, which incorporates a device used to shred uterine tissue and fibroids for removal, has been suggested to spread uterine sarcomas and Leiomyosarcoma (LMS), a deadly type of cancerous smooth muscle tumor.

Following an alert from the U.S. Food and Drug Administration (FDA) on April 17, 2014 that warned the general public about this alleged link, the attorneys at Bernstein Liebhard LLP are actively investigating potential morcellator hysterectomy lawsuits on behalf of women whose cancer may have suffered these complications.

Laparoscopic Morcellation

Following the introduction of power morcellators in 1993, the devices are now used in approximately 50,000 laparoscopic hysterectomies and myomectomies (fibroid removal surgeries) each year. During the spring of 2014, the alleged dangers of laparoscopic morcellation became a subject of concern from health regulators in the U.S. when the FDA issued a public health alert in April that discouraged doctors from conducting procedures with the devices, which consist of a hollow cylinder and sharp edges and may increase the risk for undetected cancer cells to spread into areas outside the uterus. If the cancer spreads outside the uterus and into the pelvis and abdomen, a person’s long-term rate of survival may be significantly reduced. According to the FDA alert, 1 out of 498 women who undergo a morcellator hysterectomy procedure may suffer from Leiomyosarcoma (LMS). The federal agency’s alert also announced plans to convene an advisory panel meeting on the matter in the coming months.

Hysterectomy Cancer Concerns Mount in 2014

On May 7, 2014, Health Canada issued a similar notice to hospitals in the country that warned about the possible inadvertent spread of Leiomysarcoma (LMS), uterine sarcoma and other cancers after use of the power morcellator. The regulators recommended hospitals to consider uterine fibroid treatment alternatives that do not require power morcellation, and to review different options with patients. Health Canada also suggested that if morcellators are to be used, they are put in a bag to reduce their potential of spreading cancer to the pelvic area, abdomen and other areas outside the uterus. The following companies manufacture devices that are used in laparoscopic morcellation procedures: Johnson & Johnson’s Ethicon, Inc. unit, Stortz, Richard Wolf Medical Instrumentation Company, LiNa, and Blue Endo. As of May 2014, Ethicon, Lina and Blue Endo had been blamed for injuries allegedly sustained because of their power morcellators.

According to one claim filed in March 2014, a 53-year old woman died of metatastic leiomyosarcoma less than a year after receiving a hysterectomy that used one of these devices. Her lawsuit blames Ethicon for damages allegedly sustained by its power morcellator.

How to File a Hysterectomy Cancer Lawsuit

Find out more about the alleged hysterectomy cancer association that has raised significant concern from the U.S. Food and Drug Administration (FDA) recently by calling our Firm at .